A carregar...
Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study
BACKGROUND: This study assessed the long-term safety and efficacy of tiotropium Respimat, a long-acting inhaled anticholinergic bronchodilator, in asthma, added on to inhaled corticosteroids (ICS) with or without long-acting β(2)-agonist (LABA). METHODS: 285 patients with symptomatic asthma, despite...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4404354/ https://ncbi.nlm.nih.gov/pubmed/25894430 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0124109 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|